Qualigen Therapeutics Announces Two Posters of Its RAS-Targeted Inhibitor Program at the National Cancer Institute
October 19, 2022 09:00 ET
|
Qualigen Therapeutics, Inc.
Fourth RAS Initiative Symposium Highlights Preclinical Data in Solid Tumor Models CARLSBAD, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified...